Megan Hollasch

An analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.

Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.

Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

A subgroup analysis of the phase 2 GRIFFIN trial confirmed that Black patients with newly diagnosed multiple myeloma elicited a benefit from treatment with daratumumab added to lenalidomide, bortezomib, and dexamethasone without additional toxicities.

Shanu Modi, MD, discusses the significance of the approval of trastuzumab deruxtecan for patients with HER2-low breast cancer.

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.

Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.

Results of the phase 2 CRESTONE study have demonstrated the tolerable safety profile and efficacy of seribantumab for the treatment adult patients with metastatic solid or locally advanced tumors harboring the rare NRG1 fusions.

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.